Food Science & Human Nutrition Department, University of Florida, Gainesville, FL, USA.
Institute of Medical Engineering, School of Basic Medical Science, Health Science Center, Xi'an Jiaotong University, Xi'an, China; Center for Diagnostics and Therapeutics, Institute for Biomedical Science, Georgia State University, Atlanta, GA, USA.
Mol Ther. 2019 Mar 6;27(3):493-506. doi: 10.1016/j.ymthe.2019.01.003. Epub 2019 Jan 12.
Nanoparticles (NPs) have been utilized to deliver drugs to the intestinal epithelium in vivo. Moreover, NPs derived from edible plants are less toxic than synthetic NPs. Here, we utilized ginger NP-derived lipid vectors (GDLVs) in a proof-of-concept investigation to test the hypothesis that inhibiting expression of divalent metal-ion transporter 1 (Dmt1) would attenuate iron loading in a mouse model of hereditary hemochromatosis (HH). Initial experiments using duodenal epithelial organ cultures from intestine-specific Dmt1 knockout (KO) (Dmt1) mice in the Ussing chamber established that Dmt1 is the only active iron importer during iron-deficiency anemia. Further, when Dmt1 mice were crossed with mice lacking the iron-regulatory hormone, hepcidin (Hepc), iron loading was abolished. Hence, intestinal Dmt1 is required for the excessive iron absorption that typifies HH. Additional experiments established a protocol to produce GDLVs carrying functional Dmt1 small interfering RNAs (siRNAs) and to target these gene delivery vehicles to the duodenal epithelium in vivo (by incorporating folic acid [FA]). When FA-GDLVs carrying Dmt1 siRNA were administered to weanling Hepc mice for 16 days, intestinal Dmt1 mRNA expression was attenuated and tissue iron accumulation was blunted. Oral delivery of functional siRNAs by FA-GDLVs is a suitable therapeutic approach to mitigate iron loading in murine HH.
纳米颗粒(NPs)已被用于将药物递送至体内的肠上皮细胞。此外,来源于可食用植物的 NPs 比合成 NPs 的毒性更小。在这里,我们利用姜 NP 衍生的脂质载体(GDLV)进行了概念验证研究,以检验以下假设:抑制二价金属离子转运蛋白 1(Dmt1)的表达将减轻遗传性血色素沉着症(HH)小鼠模型中的铁负荷。在 Ussing 室中使用肠特异性 Dmt1 敲除(KO)(Dmt1)小鼠的十二指肠上皮器官培养物进行的初步实验建立了 Dmt1 是缺铁性贫血期间唯一的活性铁摄取体。此外,当 Dmt1 小鼠与缺乏铁调节激素,hepcidin(Hepc)的小鼠杂交时,铁负荷被消除。因此,肠 Dmt1 是 HH 典型的过量铁吸收所必需的。进一步的实验建立了一种生产携带功能性 Dmt1 小干扰 RNA(siRNA)的 GDLV 并将这些基因传递载体靶向体内十二指肠上皮细胞的方案(通过整合叶酸(FA))。当向 16 日龄 Hepc 小鼠给予携带 Dmt1 siRNA 的 FA-GDLV 时,肠 Dmt1 mRNA 表达减弱,组织铁积累减少。通过 FA-GDLV 口服递送达功能 siRNA 是减轻 HH 小鼠铁负荷的合适治疗方法。